

Expanding Chronic Hepatitis C Treatment in Low- and Middle-Income Countries



Gilead's Treatment Access Commitment

Gilead works to enable access to its medicines for all people who can benefit from them, regardless of where they live or their economic means. In developing countries, **12.6 million patients now receive Gilead-based HIV therapies**, and 1.7 million people are estimated to receive Gilead-based chronic hepatitis C virus (HCV) therapies. This is a result of collaborations with governments, voluntary generic licensees, regional business partners, policy makers, healthcare providers, patient groups and public health entities.

Gilead is pursuing multiple strategies to **expand access to its HCV medicines** in low- and middle-income countries, prioritizing those with the greatest disease burden. **More than 71 million people worldwide are infected with HCV**, and HCV-related complications cause up to **399,000 deaths each year**.

